NUTF2 and chronic myelogenous leukemia, BCR-ABL1 positive: Should a third clone in fact be involved in the CML dynamics shaping PP15, then the question arises whether clone 3 stem cells originated (i) already during the preceding imatinib treatment period or (ii) in the course of dasatinib administration.